Search the Newsreel

Tlou Energy Sustains Exploration Spend on Borrowings as Cash Tightens

Outlook Therapeutics (OTLK) Stock Looks Cheap On Hope But Pricey On Book Value

Outlook Therapeutics (OTLK) has seen a significant stock decline over five years, but recent FDA approval for its lead drug, LYTENAVA, has brought renewed attention. While the approval provides hope for improved revenues, the stock's valuation picture remains inconclusive due to a negative shareholder …

Talon Metals (TSE:TLO) Stock Crosses Below 200 Day Moving Average - Here's Why

Outlook Therapeutics (OTLK) Is Down 24.3% After Landmark FDA Wet AMD Drug Approval - Has The Bull Case Changed?

Outlook Therapeutics (OTLK) shares dropped 24.3% following FDA approval for LYTENAVA, a drug for wet age-related macular degeneration, despite securing 12 years of exclusivity in an $8.5 billion market. The investment focus has shifted from approval to successful U.S. launch and reimbursement, but financing …

Outlook Therapeutics (OTLK) director purchases 95,398 common shares

Outlook Therapeutics director Faisal Ghiath Sukhtian purchased 95,398 shares of common stock at $1.0482 per share on July 29, 2026. This transaction increased his direct holdings to 220,972 common shares. The purchase was an open-market or private transaction and was not made under a …

Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On Friday, the U.S. Food and Drug Administration (FDA) approved Outlook Therapeutics Inc.'s ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for neovascular age-related macular degeneration (nAMD), commonly known as wet …

Outlook Therapeutics, Inc. (NASDAQ:OTLK): When Will It Breakeven?

This article examines when Outlook Therapeutics, Inc. (NASDAQ:OTLK) is expected to achieve breakeven profitability. It analyzes the company's financial performance and projections to forecast its path to profitability. The analysis helps investors understand the timeline for OTLK to become financially self-sufficient.

Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG

BTIG upgraded Outlook Therapeutics to 'Buy' with a $4 price target after the FDA approved its wet AMD therapy, Lytenava, positioning it as a potential preferred anti-VEGF treatment in the $8.5 billion U.S. retina market. Despite previous regulatory setbacks and competition from lower-cost alternatives, …

Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMD

Outlook Therapeutics (NASDAQ:OTLK) shares surged after the FDA approved LYTENAVA for wet AMD, making it the first and only FDA-approved ophthalmic formulation of bevacizumab for this condition. The positive momentum was further bolstered by a BTIG analyst upgrade from Neutral to Buy with a …

BTIG upgrades Outlook Therapeutics stock rating on FDA approval

BTIG upgraded Outlook Therapeutics (NASDAQ:OTLK) to Buy with a $4.00 price target after the FDA approved its drug LYTENAVA for wet age-related macular degeneration. The stock saw a significant increase, though InvestingPro analysis suggests it's slightly overvalued. The company is now focusing on the …

OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside

Outlook Therapeutics (OTLK) saw its stock jump after receiving FDA approval for Lytenava, its wet AMD drug. This approval, which came ahead of schedule and follows previous regulatory setbacks, positions Lytenava as the first FDA-approved bevacizumab formulation specifically for ophthalmic use. Analysts are projecting …

Talon Metals Corp. Revenue Breakdown – TSX:TLO

Talon Metals Cuts Royalty on the Tamarack Project; Shares up 6.2%

Tamarack, Minnesota--(Newsfile Corp. - July 21, 2026) - Talon Metals Corp. (TSX: TLO) (OTCID: TLOFF) ("Talon" or the "Company") today announced that it has completed the exercise of its contractual right to reduce the existing net smelter returns royalty held by Triple Flag USA …

Outlook Therapeutics Wins FDA Nod For LYTENAVA After Three Setbacks

(RTTNews) - Outlook Therapeutics (OTLK) announced that the FDA has approved LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of neovascular age-related macular degeneration (wet AMD). Wet AMD is a leading cause of vision loss in older adults, …

Outlook Therapeutics (NASDAQ:OTLK) suspended post-Lytenava approval, with funding under pressure from looming warrants

Outlook Therapeutics (NASDAQ:OTLK) shares were suspended from trading following the FDA approval of its drug Lytenava for wet age-related macular degeneration. While the approval resolves a major regulatory hurdle, the company now faces financial pressures from looming warrant exercises and the need for significant …

US FDA approves Outlook Therapeutics' eye disease drug

Outlook Therapeutics has received FDA approval for Lytenava, a drug designed to treat wet age-related macular degeneration (AMD), a leading cause of blindness in older adults. This marks the company's first entry into the U.S. market, with Lytenava specifically formulated for intravitreal administration, differentiating …

OTLK Stock Slips After Regaining Nasdaq Compliance

Outlook Therapeutics Inc. (OTLK) regained Nasdaq compliance by maintaining a closing price above $1 for ten consecutive days, removing an immediate delisting threat. Despite this, the stock slipped roughly 3.5% on the day the news broke, indicating that traders view the compliance more as …

Outlook gains approval for ophthalmic bevacizumab for wet AMD

[AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background] Shidlovski * The US FDA has approved Outlook Therapeutics' (OTLK [https://seekingalpha.com/symbol/OTLK]) Lytenava (bevacizumab-vikg) …

Outlook Therapeutics receives FDA approval for wet AMD treatment

Outlook Therapeutics Inc. (NASDAQ:OTLK) has received FDA approval for LYTENAVA (bevacizumab-vikg), its treatment for neovascular age-related macular degeneration (wet AMD). This marks the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD, offering 12 years of market exclusivity. The company expects to make LYTENAVA …

Outlook Therapeutics, Inc. Revenue Breakdown – SWB:41O

Outlook Therapeutics, Inc. (SWB:41O) reported a significant decrease in revenue, generating 1.20 million EUR last year, down from 7.47 million EUR the previous year. The Ophthalmic Formulation segment was the sole contributor to this revenue, and all revenue originated from the United States.

Outlook Therapeutics grants options to CEO Robert C. Jahr and CFO Lawrence A. Kenyon

Outlook Therapeutics has granted stock options to its CEO, Robert C. Jahr, and CFO, Lawrence A. Kenyon, along with approving performance-linked cash bonuses. These awards are tied to the FDA approval of ONS-5010 and recognize their efforts in advancing the BLA through FDA review …

OTLK|Outlook Therapeutics Inc|Price:1.305|Chg%:-0.035

This article provides a comprehensive financial overview of Outlook Therapeutics Inc (OTLK), a biopharmaceutical company specializing in ophthalmic formulations. It highlights the company's relatively stable fundamentals, high growth potential, and a "Buy" rating from analysts with a target price of $5.50. Despite a recent …

Outlook Therapeutics (OTLK) CEO granted 100,000 stock options

Outlook Therapeutics, Inc. (OTLK) CEO Robert Charles Jahr was granted 100,000 stock options at an exercise price of $1.4304 per share under the company's 2024 Equity Incentive Plan. These options, granted on July 21, 2026, will vest fully on July 21, 2027, and expire …

Outlook Therapeutics (NASDAQ: OTLK) grants 210,078 stock options to CFO

Outlook Therapeutics, Inc. reported that its Chief Financial Officer, Lawrence A. Kenyon, was granted 210,078 stock options on July 21, 2026. These options, under the company's 2024 Equity Incentive Plan, have an exercise price of $1.4304 per share, vest completely on July 21, 2027, …

Outlook Therapeutics Inc. (OTLK) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Outlook Therapeutics Inc. (OTLK) stock on NASDAQ, showing its current price and daily performance. It also includes sections for analyst ratings and earnings information, though specific data for OTLK's earnings and analyst targets is currently unavailable. …

OTLK Stock Slips As Warrant Resale Overhang Builds

Outlook Therapeutics Inc. (OTLK) stock recently slipped by 7.75% due to investor concerns over its FDA regulatory outcome and a significant warrant resale overhang. The company registered approximately 17.3 million shares tied to warrants and 17.26 million common shares for potential resale by existing …

Outlook Therapeutics, Inc. SEC Filing (Jul 22, 2026)

This article reports on an SEC Filing (Form EFFECT) by Outlook Therapeutics, Inc. (OTLK) dated July 22, 2026, which is categorized as having a neutral impact and sentiment. The filing indicates an effectiveness date of July 21, 2026, for an S-3 form. The article …

Outlook Therapeutics Company Profile & Introduction

This document provides a company profile and introduction for Outlook Therapeutics. The article serves as a foundational overview of the company, likely detailing its operations, mission, and position within its industry.

Outlook Therapeutics Shareholders Approve Major Capital Changes

Outlook Therapeutics shareholders have approved significant changes to the company's capital structure, including an increase in authorized common shares to 600 million and the authorization for a reverse stock split. These moves aim to provide financial flexibility for strategic initiatives, manage share price, and …

Form S-3 OUTLOOK THERAPEUTICS INC For: 17 July By Investing.com

This article announces that OUTLOOK THERAPEUTICS INC filed a Form S-3 on July 17. The filing is brief and primarily serves as a news item about the regulatory document, without providing further details on the content or implications of the S-3 filing itself. The …

Outlook Therapeutics Registers 17.3 Million Shares for Resale

Outlook Therapeutics has registered 17.3 million shares for resale by various selling shareholders. These shares were issued as part of a private placement during the first quarter of fiscal year 2024. The filing aims to allow these shareholders to resell their restricted shares in …

Outlook Therapeutics files prospectus for 17.258M share offering

Outlook Therapeutics has filed a prospectus with the SEC for the sale of 17.258 million common shares by existing selling stockholders. The company will not receive any proceeds from this offering, which allows current shareholders to offload their stakes. This regulatory filing provides transparency …

Outlook Therapeutics (NASDAQ: OTLK) files resale for 17.3M warrant-linked shares

Outlook Therapeutics has filed a Form S-3 registration statement for the resale of up to 17,258,065 shares of common stock, which are issuable upon the exercise of warrants from an April 23, 2026 financing. The company will not receive proceeds directly from the resale …

Outlook Therapeutics (NASDAQ: OTLK) backs share increase, reverse split

Outlook Therapeutics (NASDAQ: OTLK) stockholders approved several key proposals at a special meeting on July 16, 2026. These include increasing the authorized common stock from 260 million to 600 million shares, approving the potential issuance of common shares underlying warrants from an April 2026 …

OTLK Stock Tightens Range As Traders Watch Support

Outlook Therapeutics Inc. (OTLK) stock is experiencing a tightening trading range between the mid-$1.50s and high-$1.70s, signaling consolidation after recent volatility. The company, a clinical-stage biotech, faces significant financial challenges including low revenue, substantial losses, negative working capital, and ongoing dilution risk. Traders are …

$Outlook Therapeutics (OTLK.US)$ looks like a cup and handle on the daily ans weekly chart. this should take off soon.

An analyst from the moomoo community, "Empchief," observes that Outlook Therapeutics (OTLK.US) displays a "cup and handle" pattern on its daily and weekly charts. This technical analysis suggests that the stock is poised for an upward movement in the near future.